Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 12, 2026, 2:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 573 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Novo Nordisk A/S Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.

NCT02648204
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
semaglutide, Dulaglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
100
States / cities
Tuscumbia, Alabama • Chandler, Arizona • Phoenix, Arizona + 85 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Oct 12, 2026, 2:17 PM EDT
Completed Not applicable Interventional Results available

The Effect and Safety of a Novel CGM-Based Titration Algorithm for Basal Insulin in T2DM Participants.

NCT06111508
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Continuous Glucose Monitoring (CGM)-based titration algorithm implemented in DiAs
Device
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
New York, New York • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 12, 2026, 2:17 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Accelerated Genital Tract Aging in HIV: Estradiol Clinical Trial

NCT04079218
View directory record Official record
Conditions
HIV Infection, Vaginal Atrophy, Menopause, Menopause Related Conditions, Aging, Premature Aging, Atrophic Vaginitis, Dysbiosis, Vaginitis
Interventions
Estradiol Vaginal Insert
Drug
Lead sponsor
Kerry Murphy
Other
Eligibility
45 Years to 70 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 14, 2025 · Synced Oct 12, 2026, 2:17 PM EDT
Completed No phase listed Observational

A Master Protocol for Semaglutide Effects on Cardiovascular and Obesity-related Outcomes in People With Overweight or Obesity in the Real World

NCT07141914
View directory record Official record
Conditions
Overweight, Obesity, Heart Failure (HF), Atherosclerotic Cardiovascular Disease (ASCVD), Primary Prevention
Interventions
No treatment given
Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
45 Years and older
Enrollment
285,327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Plainsboro, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 12, 2026, 2:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Investigation on Safety, Tolerability and Pharmacokinetics of Single Doses of NNC0174-0833 in Normal Weight, Overweight to Obese But Otherwise Healthy Male Subjects

NCT02300844
View directory record Official record
Conditions
Metabolism and Nutrition Disorder, Obesity
Interventions
NNC0174-0833, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
22 Years to 64 Years · Male only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Oct 12, 2026, 2:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Research Study Looking Into Blood Levels of NNC0174-0833 in People With Normal and Impaired Kidney Function

NCT04209049
View directory record Official record
Conditions
Overweight, Obesity
Interventions
NNC0174-0833
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Oct 12, 2026, 2:17 PM EDT
Completed Phase 3 Interventional Results available

A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)

NCT04865770
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Chronic Kidney Disease
Interventions
Semaglutide, Placebo (Semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
20
States / cities
Tucson, Arizona • Los Angeles, California • National City, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 12, 2026, 2:17 PM EDT
Completed Phase 3 Interventional Results available

The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes

NCT00856986
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, insulin detemir, metformin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 84 Years
Enrollment
987 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
60
States / cities
Alexander City, Alabama • Birmingham, Alabama • Encino, California + 49 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Oct 12, 2026, 2:17 PM EDT
Completed Phase 4 Interventional Results available

Comparison of the Blood Sugar Lowering Effect and Safety of Two Insulin Treatments in Type 2 Diabetes

NCT00537303
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin detemir, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
20
States / cities
Fresno, California • Mission Viejo, California • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2017 · Synced Oct 12, 2026, 2:17 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Memory Aid by Intranasal Insulin in Diabetes (MemAID)

NCT02415556
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Regular Human Insulin, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
50 Years to 85 Years
Enrollment
289 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 19, 2022 · Synced Oct 12, 2026, 2:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Look at How Safe a New Medicine (NNC0491-6075) is in Healthy People and in Participants With High Levels of Fat in the Blood

NCT05979428
View directory record Official record
Conditions
Healthy Volunteers, Dyslipidaemia
Interventions
NNC0491-6075, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 12, 2026, 2:17 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Liraglutide in the Treatment of Type 1 Diabetes Mellitus

NCT01722266
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Liraglutide, Placebo
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Williamsville, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2024 · Synced Oct 12, 2026, 2:17 PM EDT
Completed Phase 3 Interventional Results available

Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome

NCT02527200
View directory record Official record
Conditions
Metabolism and Nutrition Disorder, Obesity
Interventions
liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
6 Years to 18 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
5
States / cities
Santa Monica, California • Baltimore, Maryland • Buffalo, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Oct 12, 2026, 2:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Research Study to Investigate How a Study Medicine (NNC9204- 1177) Affects Blood Levels of Other Medicines in Healthy People

NCT04059367
View directory record Official record
Conditions
Healthy Volunteers, Overweight, Obesity
Interventions
NNC9204-1177, Cocktail of 5 already approved drugs
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 60 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Oct 12, 2026, 2:17 PM EDT
Completed Phase 1 Interventional

A First-in-human Research Study on How NNC0662-0419 Works in People Living With Overweight or Obesity

NCT06737536
View directory record Official record
Conditions
Overweight, Obesity
Interventions
NNC0662-0419, Placebo (NNC0662-0419)
Drug · Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
19 Years to 55 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 19, 2025 · Synced Oct 12, 2026, 2:17 PM EDT
Completed Phase 4 Interventional Results available

Lifestyle Modification and Liraglutide

NCT02911818
View directory record Official record
Conditions
Obesity
Interventions
CMS-recommended lifestyle counseling, Liraglutide 3.0mg, Portion-Controlled Diet, Placebo Oral Tablet, Phentermine 15 MG, Extension Study CMS-recommended lifestyle counseling
Behavioral · Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Oct 12, 2026, 2:17 PM EDT
Recruiting No phase listed Observational

ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders

NCT04398628
View directory record Official record
Conditions
Hematologic Disorder, Bleeding Disorder, Connective Tissue Disorder, Hemophilia, Thrombosis, Von Willebrand Diseases, Thrombophilia, Rare Bleeding Disorder, Platelet Disorder, Factor IX Deficiency, Factor VIII Deficiency, Thalassemia, Sickle Cell Disease
Interventions
Not listed
Lead sponsor
American Thrombosis and Hemostasis Network
Network
Eligibility
Not listed
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2035
U.S. locations
76
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 60 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 12, 2026, 2:17 PM EDT
Completed Phase 1 Interventional

Pharmacokinetics of Insulin Detemir in Subjects With Type 2 Diabetes

NCT01497600
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin detemir, insulin NPH
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2017 · Synced Oct 12, 2026, 2:17 PM EDT
Completed Phase 1 Interventional

Bioequivalence of Two Somatropin Products (Norditropin® Versus Genotropin®) in Healthy Adult Volunteers

NCT01401244
View directory record Official record
Conditions
Genetic Disorder, Prader-Willi Syndrome, Growth Disorder, Idiopathic Short Stature, Healthy
Interventions
somatropin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 40 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 24, 2017 · Synced Oct 12, 2026, 2:17 PM EDT
Terminated Not applicable Interventional Results available

Glycemic Stability of Insulin Aspart Versus Insulin Lispro in Insulin Pump Therapy

NCT00428207
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin Aspart versus Insulin Lispro, Insulin Lispro versus Insulin Aspart
Drug
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 12, 2026, 2:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Research Study on How NNC0487-0111 Works in People With Overweight or Obesity

NCT05369390
View directory record Official record
Conditions
Obesity
Interventions
NNC0487-0111 A, NNC0487-0111 B, Placebo B (NNC0487-0111 B), Placebo A (NNC0487-0111 A)
Drug · Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2025 · Synced Oct 12, 2026, 2:17 PM EDT
Terminated Phase 1 Interventional

Efficacy of Activated Recombinant Human Factor VII in Healthy Volunteers Treated for Punch Biopsy Mediated Bleeding

NCT01561950
View directory record Official record
Conditions
Haemostasis, Healthy
Interventions
eptacog alfa (activated), clopidogrel, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 23, 2016 · Synced Oct 12, 2026, 2:17 PM EDT
Completed No phase listed Observational

Natural History of Patients With PH3 and a History of Stone Events

NCT04542590
View directory record Official record
Conditions
Primary Hyperoxaluria Type 3
Interventions
Not listed
Lead sponsor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Industry
Eligibility
2 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Oct 12, 2026, 2:17 PM EDT
Completed Phase 4 Interventional

Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery

NCT01561391
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Interventions
activated recombinant human factor VII, factor IX, factor VIII
Drug · Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
5 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
14
States / cities
Los Angeles, California • Chicago, Illinois • New Orleans, Louisiana + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2023 · Synced Oct 12, 2026, 2:17 PM EDT